REGISTERED
on 20 Jul 2021
Last Applicant/ Owned by
1 Burlington Road
Dublin
IE
Serial Number
87700839 filed on 29th Nov 2017
Registration Number
6428572 registered on 20th Jul 2021
Filing Basis
1. intent to use
2. use application currently
Disclaimer
NO DATA
LYBALVI
Pharmaceutical preparations for the treatment of psychiatric and neurodegenerative diseases and disorders including schizophrenia, depression, major depressive disorder, stress, anxiety, treatment resistant depression, bipolar depression, bipolar disorder; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidemia
Classification Information
Class [005]
Pharmaceutical Products
Pharmaceutical preparations for the treatment of psychiatric and neurodegenerative diseases and disorders including schizophrenia, depression, major depressive disorder, stress, anxiety, treatment resistant depression, bipolar depression, bipolar disorder; pharmaceutical preparations for the mitigation of weight gain and the treatment of metabolic diseases and dyslipidemia
First Use Date in General
19th Apr 2021
First Use Date in Commerce
19th Apr 2021
Mark Details
Serial Number
No 87700839
Mark Type
No Service/Collective Mark
Attorney Docket Number
No 029318-2784
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
No
66A Current
No
Current Basis
No
No Basis
No
Legal History
| Status Date | Action Taken |
|---|---|
| 20th Jul 2021 | REGISTERED-PRINCIPAL REGISTER |
| 17th Jun 2021 | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| 16th Jun 2021 | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| 17th May 2021 | SU - NON-FINAL ACTION - WRITTEN |
| 17th May 2021 | NON-FINAL ACTION E-MAILED |
| 17th May 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| 26th Apr 2021 | STATEMENT OF USE PROCESSING COMPLETE |
| 22nd Apr 2021 | USE AMENDMENT FILED |
| 22nd Apr 2021 | TEAS STATEMENT OF USE RECEIVED |
| 10th Nov 2020 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |